TY - JOUR T1 - Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein JF - medRxiv DO - 10.1101/2021.01.12.20249080 SP - 2021.01.12.20249080 AU - Tanya Golubchik AU - Katrina A. Lythgoe AU - Matthew Hall AU - Luca Ferretti AU - Helen R. Fryer AU - George MacIntyre-Cockett AU - Mariateresa de Cesare AU - Amy Trebes AU - Paolo Piazza AU - David Buck AU - John A. Todd AU - The COVID-19 Genomics UK (COG-UK) consortium AU - Christophe Fraser AU - David Bonsall Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/15/2021.01.12.20249080.abstract N2 - A new variant of SARS-CoV-2 has emerged which is increasing in frequency, primarily in the South East of England (lineage B.1.1.7 (1); VUI-202012/01). One potential hypothesis is that infection with the new variant results in higher viral loads, which in turn may make the virus more transmissible. We found higher (sequence derived) viral loads in samples from individuals infected with the new variant with median inferred viral loads were three-fold higher in individuals with the new variant. Most of the new variants were sampled in Kent and Greater London. We observed higher viral loads in Kent compared to Greater London for both the new variant and other circulating lineages. Outside Greater London, the variant has higher viral loads, whereas within Greater London, the new variant does not have significantly higher viral loads compared to other circulating lineages. Higher variant viral loads outside Greater London could be due to demographic effects, such as a faster variant growth rate compared to other lineages or concentration in particular age-groups. However, our analysis does not exclude a causal link between infection with the new variant and higher viral loads. This is a preliminary analysis and further work is needed to investigate any potential causal link between infection with this new variant and higher viral loads, and whether this results in higher transmissibility, severity of infection, or affects relative rates of symptomatic and asymptomatic infectionDocument Description and Purpose This is an updated report submitted to NERVTAG in December 2020 as part of urgent investigations into the new variant of SARS-COV-2 (VUI-202012/01). It makes full use of (and is restricted to) all sequence data and associated metadata available to us at the time this original report was submitted and remains provisional. Under normal circumstances more genomes and metadata would be obtained and included before making this report public. We will update this preprint when more genomes and metadata are available and before submitting for peer review.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. This research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. KAL is supported by The Wellcome Trust and The Royal Society (107652/Z/15/Z). MH, LF, MdC, GMC, DB, CF and TG are supported by Li Ka Shing Foundation funding awarded to CF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COVID-19 Genomics UK (COG-UK) consortium study protocol was approved by the Public Health England Research Ethics and Governance Group (reference: R&D NR0195) on the 8th of April 2020. The decision was communicated to Professor Sharon Peacock by Dr Elizabeth Coates, Head of Research Governance, PHE Research Support and Governance Office.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data has been made publicly available as part of the COVID-19 Genomics UK (COG-UK) Consortium via GISAID and via the European Nucleotide Archive (ENA) study PRJEB37886. ER -